Former Surgeon General Calls for Clinician-Guided Framework to Regulate Popular Peptides

Jerome Adams, the former U.S. surgeon general, argues that the FDA should adopt a middle‑ground strategy rather than banning peptide compounds outright. He notes the rapid growth of peptide use for recovery, sleep, performance, metabolic health and longevity, often sourced from unregulated online sellers without medical supervision or reliable quality control.

Adams points out that the current gray‑market environment creates safety risks that regulators aim to avoid. With Kyle Diamantas serving as acting FDA commissioner, he sees an opportunity for the agency to shape policy that balances access with oversight.

He recommends that the FDA develop a structured, clinician‑guided framework, citing the upcoming Pharmacy Compounding Advisory Committee meeting on July 23‑24, which will consider restoring certain peptides for compounding by licensed 503A pharmacies. Such a framework would bring demand under professional oversight while maintaining rigorous safety standards.